https://sc79activator.com/id-o....f-moving-endocan-1-a
BACKGROUND Purine nucleoside analogs (PNAs) will be the recommended first-line treatment for patients with hairy mobile leukemia (HCL), however they are involving unpleasant activities (AEs). Because of too little real-world proof regarding AEs being connected with PNAs, we used commercial data to evaluate AE rates, AE-related health care resource usage (HCRU), and costs among PNA-treated patients with HCL. Adults aged ≥18 years with ≥2 claims for HCL ≥30 days aside from 1 January 20
Like
Comment
Share
